The purpose of this prospective study is to characterize the natural history of ENPP1 Deficiency and the early-onset form of ABCC6 Deficiency longitudinally. The study will prospectively gather information about the biochemical, physiological, anatomic, radiographic, and functional manifestations (including patient reported outcomes) of each disease.
Study INZ701-003 is a multicenter, prospective, longitudinal, observational study to evaluate disease presentation, progression, and burden of illness in pediatric subjects aged 2 to \<18 years with ENPP1 Deficiency and the early-onset form of ABCC6 Deficiency. Subjects will receive care available at the clinical site along with additional assessments administered by the study team. To participate in this study, subjects will give informed assent and parents/guardians will provide informed consent. Subject participation will consist of a Screening Period and an Observation Period. Assessments will be performed at each visit as indicated in the Schedule of Events. During the Screening Period, assessments will be performed to determine eligibility. Screening and Baseline assessments may be conducted on the same day if the Investigator determines that the patient can successfully complete all study procedures in one day due to their age. If not, sites may schedule additional visits, as needed. A subject will be enrolled into the study if they meet all eligibility criteria. During the Observation Period, subjects will be assessed for changes in their disease in the following areas: measurements of physiological function (including laboratory testing and anatomical and radiographical assessment of calcification and bone mineralization); performance outcomes; patient, caregiver, and physician reported outcomes; and healthcare utilization.
Study Type
OBSERVATIONAL
Enrollment
12
No Intervention for this observational study
Boston Children's Hospital
Boston, Massachusetts, United States
CHOP - Robers Center for Pediatric Research
Philadelphia, Pennsylvania, United States
Cook Children's Hospital
Fort Worth, Texas, United States
CHU Sainte-Justine
Montreal, Quebec, Canada
Royal Manchester University Hospital
Manchester, United Kingdom
Measurement of Plasma Inorganic Pyrophosphate (PPi) in Plasma
For each subject, blood plasma will be assayed for Plasma Inorganic Pyrophosphate (PPi), comparing the subjects baseline value over time
Time frame: Up to 12 months
Determination of Arterial Calcification
For each subject, occurrence of arterial calcification will be examined
Time frame: Up to 12 months
Determination of Organ Calcification
For each subject, occurrence of organ calcification will be examined
Time frame: Up to 12 months
Determination of skeletal radiographs
For each subject, skeletal radiographs will be obtained to determine skeletal abnormalities and will be compared to baseline
Time frame: Up to 12 months
Determination of range of motion
For each subject, aged 4 to \<18 years, range of motion will be assessed comparing to subjects baseline over time
Time frame: Up to 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.